BACKGROUND: This study assessed functional performance, calf muscle characteristics, peripheral nerve function, and quality of life in asymptomatic persons with peripheral arterial disease (PAD). METHODS AND RESULTS: PAD participants (n=465) had an ankle brachial index <0.90. Non-PAD participants (n=292) had an ankle brachial index of 0.90 to 1.30. PAD participants were categorized into leg symptom groups including intermittent claudication (n=215) and always asymptomatic (participants who never experienced exertional leg pain, even during the 6-minute walk; n=72). Calf muscle was measured with computed tomography. Analyses were adjusted for age, sex, race, ankle brachial index, comorbidities, and other confounders. Compared with participants with intermittent claudication, always asymptomatic PAD participants had smaller calf muscle area (4935 versus 5592 mm(2); P<0.001), higher calf muscle percent fat (16.10% versus 9.45%; P<0.001), poorer 6-minute walk performance (966 versus 1129 ft; P=0.0002), slower usual-paced walking speed (P=0.0019), slower fast-paced walking speed (P<0.001), and a poorer Short-Form 36 Physical Functioning score (P=0.016). Compared with an age-matched, sedentary, non-PAD cohort, always asymptomatic PAD participants had smaller calf muscle area (5061 versus 5895 mm(2); P=0.009), poorer 6-minute walk performance (1126 versus 1452 ft; P<0.001), and poorer Walking Impairment Questionnaire speed scores (40.87 versus 57.78; P=0.001). CONCLUSIONS: Persons with PAD who never experience exertional leg symptoms have poorer functional performance, poorer quality of life, and more adverse calf muscle characteristics compared with persons with intermittent claudication and a sedentary, asymptomatic, age-matched group of non-PAD persons.
BACKGROUND: This study assessed functional performance, calf muscle characteristics, peripheral nerve function, and quality of life in asymptomatic persons with peripheral arterial disease (PAD). METHODS AND RESULTS: PAD participants (n=465) had an ankle brachial index <0.90. Non-PAD participants (n=292) had an ankle brachial index of 0.90 to 1.30. PAD participants were categorized into leg symptom groups including intermittent claudication (n=215) and always asymptomatic (participants who never experienced exertional leg pain, even during the 6-minute walk; n=72). Calf muscle was measured with computed tomography. Analyses were adjusted for age, sex, race, ankle brachial index, comorbidities, and other confounders. Compared with participants with intermittent claudication, always asymptomatic PAD participants had smaller calf muscle area (4935 versus 5592 mm(2); P<0.001), higher calf muscle percent fat (16.10% versus 9.45%; P<0.001), poorer 6-minute walk performance (966 versus 1129 ft; P=0.0002), slower usual-paced walking speed (P=0.0019), slower fast-paced walking speed (P<0.001), and a poorer Short-Form 36 Physical Functioning score (P=0.016). Compared with an age-matched, sedentary, non-PAD cohort, always asymptomatic PAD participants had smaller calf muscle area (5061 versus 5895 mm(2); P=0.009), poorer 6-minute walk performance (1126 versus 1452 ft; P<0.001), and poorer Walking Impairment Questionnaire speed scores (40.87 versus 57.78; P=0.001). CONCLUSIONS:Persons with PAD who never experience exertional leg symptoms have poorer functional performance, poorer quality of life, and more adverse calf muscle characteristics compared with persons with intermittent claudication and a sedentary, asymptomatic, age-matched group of non-PAD persons.
Authors: Matthew A Allison; Elena Ho; Julie O Denenberg; Robert D Langer; Anne B Newman; Richard R Fabsitz; Michael H Criqui Journal: Am J Prev Med Date: 2007-04 Impact factor: 5.043
Authors: Mary M McDermott; Robert Sufit; Takashi Nishida; Jack M Guralnik; Luigi Ferrucci; Lu Tian; Kiang Liu; Jin Tan; William H Pearce; Joseph R Schneider; Leena Sharma; Michael H Criqui Journal: Arch Intern Med Date: 2006-10-09
Authors: A T Hirsch; M H Criqui; D Treat-Jacobson; J G Regensteiner; M A Creager; J W Olin; S H Krook; D B Hunninghake; A J Comerota; M E Walsh; M M McDermott; W R Hiatt Journal: JAMA Date: 2001-09-19 Impact factor: 56.272
Authors: M M McDermott; P Greenland; K Liu; J M Guralnik; M H Criqui; N C Dolan; C Chan; L Celic; W H Pearce; J R Schneider; L Sharma; E Clark; D Gibson; G J Martin Journal: JAMA Date: 2001-10-03 Impact factor: 56.272
Authors: Ramin Shadman; Michael H Criqui; Warner P Bundens; Arnost Fronek; Julie O Denenberg; Anthony C Gamst; Mary M McDermott Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Mary M McDermott; Lu Tian; Kiang Liu; Jack M Guralnik; Luigi Ferrucci; Jin Tan; William H Pearce; Joseph R Schneider; Michael H Criqui Journal: J Am Coll Cardiol Date: 2008-04-15 Impact factor: 24.094
Authors: Mary M McDermott; Charlotte A Peterson; Robert Sufit; Luigi Ferrucci; Jack M Guralnik; Melina R Kibbe; Tamar S Polonsky; Lu Tian; Michael H Criqui; Lihui Zhao; James H Stein; Lingyu Li; Christiaan Leeuwenburgh Journal: Vasc Med Date: 2018-05-08 Impact factor: 3.239
Authors: Simon Hsu; Dena E Rifkin; Michael H Criqui; Natalie C Suder; Pranav Garimella; Charles Ginsberg; Antoinette M Marasco; Belinda J McQuaide; Emma J Barinas-Mitchell; Matthew A Allison; Christina L Wassel; Joachim H Ix Journal: J Vasc Surg Date: 2017-12-22 Impact factor: 4.268
Authors: Christina L Wassel; Matthew A Allison; Joachim H Ix; Dena E Rifkin; Nketi I Forbang; Julie O Denenberg; Michael H Criqui Journal: J Vasc Surg Date: 2016-04-29 Impact factor: 4.268